Identification and measurement of both pathological hallmarks through imaging and fluid biomarkers has caused a shift away from a clinical definition of AD towards a biological conceptualization using the AT(N) research framework, which categorizes individuals based on biomarker evidence for Aβ (A), tau (T), and neurodegeneration (N) [9]. This evidence concerns the gene MAPT and Alzheimer disease.